Lead CNS Asset Lead asset azetukalner is in Phase 3 for epilepsy, major depressive disorder, and bipolar depression, underscoring a high-value CNS focus and strong potential for licensing or co-commercialization deals to accelerate global access.

Capital and Leadership Recent financing activity and a CFO appointment signal a robust capital runway and readiness to execute large-scale business development, upfronts, milestones, and strategic alliances.

North American Footprint Offices in Vancouver and Boston position Xenon for US and Canadian partnerships, regional rights discussions, and access to key clinical networks for trials and commercialization.

Diversified Pipeline An early-stage Kv7 and Nav1.7 portfolio targeting pain along with CNS indications creates multiple external collaboration paths, including license-outs or co-development in non-core territories.

Strategic Outreach Ongoing scientific engagement and data presentations at major conferences indicate a partner-friendly posture and potential to accelerate due diligence, collaborations, and data-driven licensing discussions.